Modeling mechanisms of in vivo variability in methotrexate accumulation and folate pathway inhibition in acute lymphoblastic leukemia cells.
Modeling mechanisms of in vivo variability in methotrexate accumulation and folate pathway inhibition in acute lymphoblastic leukemia cells.
复制标题
DOI：
10.1371/journal.pcbi.1001019
复制
发表时间：
2010-12-02
影响因子：
4.3
通讯作者：
Evans WE
中科院分区：
文献类型：
--
作者：
Panetta JC;Sparreboom A;Pui CH;Relling MV;Evans WE
Methotrexate (MTX) is widely used for the treatment of childhood acute lymphoblastic leukemia (ALL). The accumulation of MTX and its active metabolites, methotrexate polyglutamates (MTXPG), in ALL cells is an important determinant of its antileukemic effects. We studied 194 of 356 patients enrolled on St. Jude Total XV protocol for newly diagnosed ALL with the goal of characterizing the intracellular pharmacokinetics of MTXPG in leukemia cells; relating these pharmacokinetics to ALL lineage, ploidy and molecular subtype; and using a folate pathway model to simulate optimal treatment strategies. Serial MTX concentrations were measured in plasma and intracellular MTXPG concentrations were measured in circulating leukemia cells. A pharmacokinetic model was developed which accounted for the plasma disposition of MTX along with the transport and metabolism of MTXPG. In addition, a folate pathway model was adapted to simulate the effects of treatment strategies on the inhibition of de novo purine synthesis (DNPS). The intracellular MTXPG pharmacokinetic model parameters differed significantly by lineage, ploidy, and molecular subtypes of ALL. Folylpolyglutamate synthetase (FPGS) activity was higher in B vs T lineage ALL (p<0.005), MTX influx and FPGS activity were higher in hyperdiploid vs non-hyperdiploid ALL (p<0.03), MTX influx and FPGS activity were lower in the t(12;21) (ETV6-RUNX1) subtype (p<0.05), and the ratio of FPGS to γ-glutamyl hydrolase (GGH) activity was lower in the t(1;19) (TCF3-PBX1) subtype (p<0.03) than other genetic subtypes. In addition, the folate pathway model showed differential inhibition of DNPS relative to MTXPG accumulation, MTX dose, and schedule. This study has provided new insights into the intracellular disposition of MTX in leukemia cells and how it affects treatment efficacy. One of the primary agents used in the treatment of childhood acute lymphoblastic leukemia (ALL) is methotrexate (MTX). By better understanding its intracellular disposition, we are able to better design treatments that circumvent drug resistance and thus help improve ALL cure rates. In this study, we develop a system of mathematical models that describe the intracellular disposition of MTX along with its inhibition of important biosynthetic pathways necessary for cell division. First, we used the models to describe the disposition of intracellular MTX in a cohort of 194 patients enrolled on St. Jude Total XV protocol for newly diagnosed ALL. The results of this modeling allowed us to determine mechanisms of in vivo variability in MTX accumulation. These mechanisms related to both the influx and efflux of the drug along with the enzymes related to its metabolism. Next, we used model simulations to show the effects of changes in MTX dose and schedule on its efficacy. The results of these simulations show that longer infusions yield better efficacy and that higher MTX doses can circumvent resistance observed in ALL subtypes with lower intracellular MTX accumulate. The results from this study provide new insights into the design of more effective therapy for pediatric ALL.
登录
查看更多内容
影响因子：
15.8
作者：
Sorich MJ;Pottier N;Pei D;Yang W;Kager L;Stocco G;Cheng C;Panetta JC;Pui CH;Relling MV;Cheok MH;Evans WE
通讯作者：
Evans WE
影响因子：
1.2
作者：
Dordelmann, M;Reiter, A;Schrappe, M
通讯作者：
Schrappe, M
DOI：
10.1056/nejmoa0900386
发表时间：
2009-06-25
期刊：
The New England journal of medicine
影响因子：
--
作者：
Pui CH;Campana D;Pei D;Bowman WP;Sandlund JT;Kaste SC;Ribeiro RC;Rubnitz JE;Raimondi SC;Onciu M;Coustan-Smith E;Kun LE;Jeha S;Cheng C;Howard SC;Simmons V;Bayles A;Metzger ML;Boyett JM;Leung W;Handgretinger R;Downing JR;Evans WE;Relling MV
通讯作者：
Relling MV
影响因子：
20.3
作者：
French, Deborah;Yang, Wenjian;Relling, Mary V.
通讯作者：
Relling, Mary V.
影响因子：
--
作者：
Nijhout, H. Frederik;Reed, Michael C.;Ulrich, Cornelia M.
通讯作者：
Ulrich, Cornelia M.